Quidel Corporation
| Public | |
| Traded as | NASDAQ: QDEL |
| Industry | Pharmaceutical Industry |
| Founded | 1979 |
| Headquarters | San Diego, California, United States |
Key people |
Douglas C. Bryant, President & CEO Randall J. Steward, CFO [1] |
| Products | Diagnostic healthcare manufacturer |
| Website |
www |
Quidel Corporation (Nasdaq: QDEL) is a California-based leading diagnostic healthcare manufacturer serving to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system.
Quidel commenced operations in 1979 and launched its first products in 1984. Since that time, Quidel has expanded its product base through internal development and acquisition with a focus on increasing its research and development efforts to accelerate the rate of new product introductions. Our core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development. Our current products fall generally into these categories: (1) lateral flow, where we are market leaders in infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); and (5) molecular diagnostic products including the world’s first FDA-cleared handheld molecular device, AmpliVue. Additional molecular and Sofia tests are currently in development or in clinical trials as part of a robust product pipeline.
Products
The company's products include many globally sold branding assays such as QuickVue®, Thyretain® and the new Sofia® and AmpliVue® brands, which focuses on diagnosing influenza, thyroid disease and many other diseases and can improve the healthcare quality of hospitals.[2]
During 2011, the US Food and Drug Administration (FDA) and the European Conformity Mark in Europe provided the company with 510(k) clearance for selling Sofia Analyzer, and another 510(k) clearance for the Quidel Molecular hMPV Assay.[3]
Corporate Affairs
Quidel Corporation was formed in 1991 when Quidel and Monoclonal Antibodies merged.[4]
Acquisition
In 2013, the company acquired BioHelix Corporation (BioHelix), which was established in 2004,[5] and will pay $10 million to the BioHelix shareholders.[6]
In 2010, the Company acquired Diagnostic Hybrids, Inc. a privately held in vitro diagnostic company.[7]
In 2000, the Company acquired Litmus Concepts, Inc., a privately held in vitro diagnostic company.[8]
In 1999, the Company acquired Metra Biosystems, Inc.to participate in bone health assessment.[9]
References
- ↑ Plunkett, Jack W. (1 October 2008). Plunkett's Health Care Industry Almanac 2009 (E-Book): Health Care Industry Market Research, Statistics, Trends and Leading Companies. Plunkett Research, Ltd. p. 598. ISBN 9781593921323.
- ↑ http://finance.yahoo.com/news/quidel-present-cowen-34th-annual-223000441.html
- ↑ http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=QDEL.O
- ↑ Mamo, Laura (August 14, 2007). Queering Reproduction: Achieving Pregnancy in the Age of Technoscience. Duke University Press. p. 266. ISBN 9780822390220.
- ↑ https://www.google.com/finance?q=QDEL
- ↑ http://article.wn.com/view/2013/05/06/Quidel_Completes_Acquisition_of_BioHelix_Corporation/
- ↑ "Quidel Corporation (QDEL) to Buy Diagnostic Hybrids, Inc. for $130 Million".
- ↑ "QUIDEL CORPORATION COMPLETES ACQUISITION OF LITMUS CONCEPTS".
- ↑ "Quidel Corporation Completes Acquisition of Metra Biosystems;".